Cancer pathogenesis is extremely complex, possibly by many genes participation or single gene process, therefore in view of the identical kind of cancer, usually develop the different pathogenesis medicine. Now we have the technology of next generation sequence and have the multi-gene examination, gives the reference of treatment direction.
52 genes for once testing
Detecting method is next generation sequencing and coverage is 1500X.
Medicine data bases are include USFDA, NCCN guideline, EMA, ESMO and clinical trial III.
genetic consulting --> filling in the consent form --> FFPE sample --> analysis in the LAB --> report consulting with clinician